What is the recommended management for ALK‑negative anaplastic large cell lymphoma?

Management of ALK-Negative Anaplastic Large Cell Lymphoma

For ALK-negative ALCL, brentuximab vedotin plus CHP (cyclophosphamide, doxorubicin, prednisone) is the preferred first-line treatment (Category 1 recommendation), based on FDA approval and superior outcomes demonstrated in the ECHELON-2 trial. 1

First-Line Treatment Approach

Preferred Regimen

• Brentuximab vedotin + CHP is the Category 1 preferred regimen for all systemic ALCL, including ALK-negative disease 1
• This combination demonstrated superior progression-free survival (PFS) compared to standard CHOP in the ECHELON-2 trial, with estimated 5-year PFS rates of 60% versus 48% specifically in the ALCL subset 1
• The 5-year overall survival (OS) rates were 69% versus 60% for brentuximab vedotin + CHP compared to CHOP 1

Alternative Regimens (when brentuximab vedotin unavailable or contraindicated)

• CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) 1
• CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone) 1
• Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) 1

Important caveat: Treatments containing both anthracycline and etoposide (like CHOEP) were associated with superior OS in a large prospective cohort study of 235 ALK-negative ALCL patients 2

Treatment Duration and Staging Considerations

Early Stage Disease (Stage I-II)

• 6 cycles of multiagent chemotherapy with or without involved-site radiation therapy (ISRT), or 3-4 cycles with ISRT 1

Advanced Stage Disease (Stage III-IV)

• 6 cycles of multiagent chemotherapy alone 1

First-Line Consolidation

Consider consolidation with high-dose therapy and autologous stem cell rescue (HDT/ASCR) in responding patients, particularly those with advanced-stage disease or intermediate-to-high International Prognostic Index (IPI) scores 1

Key Points About Consolidation:

• Achievement of complete remission (CR) before HDT/ASCR is an independent predictor of improved survival 1
• The benefit of consolidation remains controversial, with retrospective studies showing conflicting results 1
• In ECHELON-2, patients who received HCT in CR1 appeared to have superior PFS, but the benefits of brentuximab vedotin + CHP were retained regardless of HCT 1
• HDT/ASCR is reasonable only in patients responding to induction therapy, though it is associated with high relapse rates 1

Prognostic Stratification: DUSP22 and TP63 Rearrangements

Critical prognostic consideration: ALK-negative ALCL is genetically heterogeneous with widely disparate outcomes based on molecular markers 3

Genetic Subgroups and Their Outcomes:

• DUSP22-rearranged (30% of cases): 5-year OS of 90%, 5-year PFS of 57% - favorable prognosis 4, 3
• TP63-rearranged (8% of cases): 5-year OS of 17% - very poor prognosis 3
• Triple-negative (DUSP22-NR/TP63-NR/ALK-negative): 5-year OS of 42%, 5-year PFS of 26% - intermediate prognosis 4, 3

Clinical implication: DUSP22-rearranged ALK-negative ALCL has a prognosis similar to ALK-positive disease and may be treated according to the ALK-positive algorithm 1

Distinctive Features of DUSP22-Rearranged Disease:

• More frequent CD3 expression (62% vs 35%) 4
• Less commonly cytotoxic phenotype (27% vs 82%) 4
• More frequent bone involvement at diagnosis (32% vs 13%) 4

Relapsed/Refractory Disease

Preferred Regimens:

• Brentuximab vedotin (monotherapy) - FDA approved for systemic ALCL after failure of at least one prior multiagent chemotherapy 1
  • ORR of 86% (66% CR) in relapsed/refractory systemic ALCL 1
  • 5-year OS rate of 61% and PFS rate of 39% for ALK-negative ALCL specifically 1
  • Median duration of response: 26 months 1

Other Recommended Options:

• Belinostat (HDAC inhibitor) 1
• Romidepsin (HDAC inhibitor) 1
• Pralatrexate 1
• Gemcitabine 1
• Bendamustine 1

Common Pitfalls and Caveats

Diagnostic Challenges:

• CD30 expression interpretation is not universally standardized; responses to brentuximab vedotin have been observed at all levels of CD30 expression, including very low levels 1
• ALK-negative ALCL often shows T-cell antigen loss and can have a "null" immunophenotype, potentially causing confusion with other neoplasms 5
• Rare cases co-express CD15 and may resemble classic Hodgkin lymphoma 6

Treatment Considerations:

• Peripheral neuropathy is the most common adverse event with brentuximab vedotin (57% of patients), though it improves or resolves with long-term follow-up in most cases 1
• Grade ≥3 adverse events with brentuximab vedotin + CHP include neutropenia (35%), anemia (13%), diarrhea (6%), peripheral neuropathy (4%), and nausea (2%) 1

Prognosis:

• Overall, ALK-negative ALCL has worse outcomes than ALK-positive disease, with 5-year OS rates of 49% and PFS rates of 43% in large prospective cohorts 2
• Performance status and DUSP22 status are the most significant factors affecting PFS in multivariate analysis 4